Less than $10/month! View ALL results for your Stocks, ETFs and Funds Screeners with Barchart Plus. FREE 30 Day Trial
or

Pharming Group N.V. ADR (PHAR)

Pharming Group N.V. ADR (PHAR)
7.80 x 1 9.00 x 3
Post-market by (Cboe BZX)
8.58 +0.31 (+3.75%) 04/24/25 [NASDAQ]
7.80 x 1 9.00 x 3
Post-market 8.58 unch (unch) 15:42 ET
News & Headlines for Thu, Apr 24th, 2025
Watch
    Add or delete the symbol from one or more Watchlists.
Pharming Group to participate in September investor conferences

/PRNewswire/ -- Pharming Group N.V. ("Pharming") (Euronext Amsterdam: PHARM/Nasdaq: PHAR) announces that Pharming's management will participate in the...

PHAR : 8.58 (+3.75%)
Pharming announces first patient enrolled in Phase III clinical trial of leniolisib for the treatment of APDS in Japan

/PRNewswire/ -- Pharming Group N.V. ("Pharming" or "the Company") (EURONEXT Amsterdam: PHARM/Nasdaq: PHAR) announces that the first patient has been enrolled...

PHAR : 8.58 (+3.75%)
Pharming to nominate industry leader Dr. Richard Peters as new Chairman of the Board

/PRNewswire/ -- Pharming Group N.V. ("Pharming" or "the Company") (EURONEXT Amsterdam: PHARM/Nasdaq: PHAR) announces today that the Board of Directors has...

KA : 0.5746 (-30.69%)
XFOR : 0.1872 (-7.00%)
PHAR : 8.58 (+3.75%)
APRE : 1.6224 (+8.16%)
Pharming Group to report second quarter and first half 2023 financial results on August 3

/PRNewswire/ -- Pharming Group N.V. ("Pharming") (Euronext Amsterdam: PHARM/Nasdaq: PHAR) confirms it will report its preliminary (unaudited) second quarter...

PHAR : 8.58 (+3.75%)
Pharming announces sale of priority review voucher

/PRNewswire/ -- Pharming Group N.V. ("Pharming" or "the Company") (EURONEXT Amsterdam: PHARM/Nasdaq: PHAR) announces that it has entered into a definitive...

PHAR : 8.58 (+3.75%)
Pharming Group to attend the following Investor Conferences in June

/PRNewswire/ -- Pharming Group N.V. ("Pharming") (Euronext Amsterdam: PHARM/Nasdaq: PHAR) announces that Pharming's management will attend the following...

PHAR : 8.58 (+3.75%)
Pharming Group reports financial results for the first quarter of 2023

FDA approval and commercial launch of Joenja® (leniolisib) in the U.S. Joenja® launch off to strong start with 23 U.S. patients on paid therapy Revenues...

PHAR : 8.58 (+3.75%)
Pharming to attend the H.C. Wainwright BioConnect Investor Conference 2023

/PRNewswire/ -- Pharming Group N.V. ("Pharming") (Euronext Amsterdam: PHARM) (Nasdaq: PHAR) announces that Pharming's Chief Executive Officer, Sijmen de Vries...

PHAR : 8.58 (+3.75%)
Pharming to attend the Van Lanschot Kempen Life Sciences Conference 2023

/PRNewswire/ -- Pharming Group N.V. ("Pharming") (Euronext Amsterdam: PHARM) (NASDAQ: PHAR) announces that Pharming's Chief Executive Officer, Sijmen de Vries...

PHAR : 8.58 (+3.75%)
Notice of First Quarter 2023 Results

/PRNewswire/ -- Pharming Group N.V. ("Pharming") (Euronext Amsterdam: PHARM) (Nasdaq: PHAR) confirms it will announce first quarter 2023 financial results for...

PHAR : 8.58 (+3.75%)

Barchart Exclusives

1 ‘Strong Buy’ Dividend Stock to Buy for an ‘America First’ World
GE Aerospace is emerging as a top “Strong Buy” dividend stock, with an 11% jump in revenue and a nearly $1 billion investment in U.S. manufacturing. Read more
Want to use this as
your default charts setting?
Save this setup as a Chart Templates
Switch the Market flag
for targeted data from your country of choice.
Open the menu and switch the
Market flag for targeted data from your country of choice.
Want Streaming Chart Updates?
Switch your Site Preferences
to use Interactive Charts
Need More Chart Options?
Right-click on the chart to open the Interactive Chart menu.
Use your up/down arrows to move through the symbols.
Free Barchart Webinar
Value Investing Philosophies: Graham, Buffett, Bogle, and EMH in Perspective